BCMA-CD19复合CAR-T细胞治疗系统性红斑狼疮:一项1期开放标签临床试验
这项单臂开放标签多中心1期研究评估BCMA-CD19复合CAR-T(cCAR)在系统性红斑狼疮伴狼疮肾炎患者中的安全性和疗效,患者停用所有SLE药物及预处理后接受3×10^6 cCAR细胞/kg。结果提示cCAR治疗安全有效,可诱导无药物缓解并清除致病性自身抗体。
要点
- P3至P13(除P11外)接受3×10^6 cCAR细胞/kg后3个月所有自身抗体阴性,补体恢复正常。
- 上述患者实现症状及无药物缓解,随访至46个月;B细胞在cCAR后2至6个月完全恢复。
- SLE疾病活动指数2000均值从基线10.6降至3个月时2.7,10例狼疮肾炎患者肾功能在90天内显著改善。
核心结论
- 数据提示cCAR治疗在诱导无药物缓解和清除SLE患者致病性自身抗体方面安全有效。
研究设计与样本
- 单臂开放标签多中心1期研究,纳入活检证实的III至V型狼疮肾炎的SLE患者,依次接受3×10^6 cCAR细胞/kg,停用所有SLE药物及预处理后给药,主要终点为安全性和毒性。
主要发现
- P1和P2实现SLE症状及无药物缓解,并获淋巴瘤完全缓解。
- P3至P13(除P11外)接受初始剂量3×10^6 cCAR细胞/kg,cCAR后3个月所有自身抗体阴性(包括长寿命浆细胞来源者),补体恢复正常。
- 这些患者实现症状及无药物缓解,cCAR后随访至46个月;B细胞在cCAR后2至6个月完全恢复。
- SLE疾病活动指数2000均值从基线10.6降至3个月时2.7;10例狼疮肾炎患者肾功能在cCAR后90天内显著改善。
- cCAR T治疗耐受良好,仅见轻度细胞因子释放综合征。
关键数值与推荐
- P11因淋巴细胞计数不足按同情用药减量给药。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aims to evaluate the safety and efficacy of BCMA-CD19 compound chimeric antigen receptor T cells (cCAR) to dual reset the humoral and B cell immune system in patients with systemic lupus erythematosus (SLE) with lupus nephritis (LN). METHODS: This is a single-arm open-label multicentre phase 1 study of BCMA and CD19-directed cCAR in patients suffering from SLE/LN with autoantibodies produced by B cells and plasma/long-lived plasma cells. In this clinical trial, we sequentially assigned biopsy-confirmed (classes III-V) LN patients to receive 3×106 cCAR cells/kg postcessation of all SLE medications and conditioning. The primary endpoint of safety and toxicity was assessed. Complete immune reset was indicated by B cell receptor (BCR) deep sequencing and flow cytometry analysis. Patient 11 (P11) had insufficient lymphocyte counts and was underdosed as compassionate use. RESULTS: P1 and P2 achieved symptom and medication-free remission (MFR) from SLE and complete remission from lymphoma. P3-P13 (excluding P11) received an initial dose of 3×106 cCAR cells /kg and were negative for all autoantibodies, including those derived from long-lived plasma cells, 3 months post-cCAR and the complement returned to normal levels. These patients achieved symptom and MFR with post-cCAR follow-up to 46 months. Complete recovery of B cells was seen in 2-6 months post-cCAR. Mean SLE Disease Activity Index 2000 reduced from 10.6 (baseline) to 2.7 (3 months), and renal function significantly improved in 10 LN patients ≤90 days post-cCAR. cCAR T therapy was well tolerant with mild cytokine-release syndrome. CONCLUSIONS: Data suggest that cCAR therapy was safe and effective in inducing MFR and depleting disease-causing autoantibodies in patients with SLE.
引用
- Wang W, He S, Zhang W, et al. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann Rheum Dis. 2024. PMID: 38777376. doi:10.1136/ard-2024-225785
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。